PRX-105
PB-09-001
Phase 1 small_molecule completed
Quick answer
PRX-105 for Organophosphate Exposure is a Phase 1 program (small_molecule) at Protalix BioTherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Protalix BioTherapeutics
- Indication
- Organophosphate Exposure
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed